Unraveling the Complex Relationship: Cancer and Inflammation
The intricate dance between inflammation and cancer is a fascinating yet controversial topic. While inflammation can be a double-edged sword, acting as both a catalyst and a suppressor of cancer, its role is pivotal in understanding the disease's progression and treatment.
A Historical Perspective
Since the groundbreaking observation by Virchow in the 19th century, inflammation has been recognized as a key player in cancer development. Up to 20% of cancers are linked to chronic infections, autoimmune disorders, or environmental factors, highlighting the pervasive influence of inflammation.
The Cancer-Inflammation Axis
Inflammation drives every stage of tumorigenesis, from initiation to progression, and even modulates therapeutic responses. This review delves into the complex mechanisms, translational efforts, and clinical strategies that navigate the cancer-inflammation axis.
Mechanistic Insights: Unraveling the Signaling Pathways
NF-κB and STAT3, the master regulators, promote cell survival, angiogenesis, and immunosuppression. The COX-2/PGE2 pathway drives proliferation and recruits MDSCs, while immune cells like TAMs (M2-polarized), MDSCs, Tregs, and N2 neutrophils suppress anti-tumor immunity. Single-cell analyses reveal a diverse landscape, offering potential therapeutic targets.
Cancer-Specific Examples: Uncovering the Contextual Differences
- CRC (Colorectal Cancer): Dysbiosis, activation of NF-κB/STAT3, and NLRP3 inflammasome activation are linked to poor prognosis.
- Lung Cancer: Tobacco and air pollution trigger COX-2/PGE2 and IL-6/STAT3 pathways, and KRAS mutations amplify immunosuppression.
- Breast Cancer: Obesity-associated inflammation drives MDSC and Treg accumulation, and C-reactive protein (CRP) predicts response to neoadjuvant therapy.
Immunotherapy and Inflammation: A Revolutionary Approach
Checkpoint inhibitors, such as anti-PD-1/PD-L1/CTLA-4, have revolutionized cancer treatment, offering response rates of 20-40%. However, elevated IL-6 levels predict resistance. The recently approved LAG-3 blockade (relatlimab) in 2024 opens new avenues. CAR-T therapy, effective in hematologic malignancies, faces challenges in solid tumors due to the inflammatory tumor microenvironment (TME). CRISPR-edited CAR-T cells show promise by improving persistence in inflammatory TMEs.
Translational Advances: Paving the Way for Precision Therapy
Drug repurposing offers exciting possibilities. Aspirin reduces the risk of CRC and metastasis, COX-2 inhibitors show potential in FAP, and statins are under investigation. Cytokine-targeting drugs like tocilizumab (anti-IL-6R), siltuximab (anti-IL-6), and infliximab (anti-TNF) are in clinical trials. The future holds promise with the combination of IL-6 blockade and immune checkpoint inhibitors (ICIs) in pancreatic cancer, scheduled for 2025 studies.
Inhibiting NF-κB/STAT3: A Preclinical Success
Bortezomib, a proteasome inhibitor, suppresses NF-κB, while novel STAT3 inhibitors reduce MDSCs in preclinical models. Humanized mice and multi-omics approaches, including single-cell studies in 2024, reveal spatial inflammatory niches.
Nanomedicine: Reprogramming TAMs
Lipid nanoparticles reprogram TAMs to an M1 phenotype in breast cancer models, offering a targeted approach.
Clinical Strategies and Biomarkers: Personalizing Cancer Care
Inflammatory biomarkers like CRP, IL-6, NLR, and PIV predict prognosis and response to ICIs. Predictive biomarkers include PD-L1 IHC, TMB, and MSI, with emerging ctDNA and microbiome signatures. Combination approaches with ICIs, aspirin, VEGF inhibitors, chemotherapy, or radiation are explored. In 2024, CRC trials combine ICIs with microbiome modulators. Managing irAEs with corticosteroids and TNF inhibitors is crucial, with sCD25 predicting risk.
Personalized Medicine: The Power of AI
AI-driven multi-omic models stratify patients and adjust treatment in real-time, revolutionizing personalized medicine.
Future Perspectives: Unlocking New Possibilities
The microbiome plays a crucial role, with Bifidobacterium and Akkermansia correlating with ICI response. Fecal microbiota transplantation (FMT) and CRISPR-based editing are under investigation. AI and machine learning predict prognosis and CAR-T resistance, with a 2024 Stanford model integrating imaging and text data.
Gene Editing: A Revolutionary Tool
CRISPR-Cas9 editing of exhaustion genes in CAR-T cells and RNA editing for reversible modulation offer precision control.
Single-Cell and Spatial Omics: Mapping the TME
Identifying MDSC clusters and resistance mechanisms, integrated with AI, provide a dynamic map of the TME.
Nanotechnology and Liquid Biopsies: Non-Invasive Monitoring
Nanoprobe TME monitoring and ctDNA-based inflammatory signatures predict response non-invasively.
Emerging Opportunities: Targeting Parallel Pathways
ADC-delivered anti-inflammatory payloads, rational combination therapy targeting NF-κB and STAT3 pathways, and germline pharmacogenomics for personalized anti-inflammatory treatment offer exciting possibilities.
Conclusions: A Path to Personalized Cancer Care
Chronic inflammation drives tumorigenesis, immune evasion, and therapy resistance. Integrating inflammation-targeting strategies with immunotherapy and biomarker-guided approaches paves the way for personalized cancer care. With advancements in microbiome modulation, AI, gene editing, and single-cell technologies, the field is poised for transformative progress.
Full text: https://www.xiahepublishing.com/2572-5505/JERP-2025-00045
This study was published in the Journal of Exploratory Research in Pharmacology, a leading journal in basic and clinical pharmacology research.
